View Future GrowthHaoxi Health Technology 과거 순이익 실적과거 기준 점검 0/6Haoxi Health Technology은 연평균 3.8%의 비율로 수입이 증가해 온 반면, Media 산업은 연평균 8.9%의 비율로 증가했습니다. 매출은 연평균 15.8%의 비율로 증가했습니다.핵심 정보3.83%순이익 성장률n/a주당순이익(EPS) 성장률Media 산업 성장률13.17%매출 성장률15.80%자기자본이익률-17.37%순이익률-6.50%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Apr 27First half 2026 earnings released: US$1.53 loss per share (vs US$3.20 loss in 1H 2025)First half 2026 results: US$1.53 loss per share. Revenue: US$33.8m (up 41% from 1H 2025). Net loss: US$6.88m (loss widened US$6.65m from 1H 2025).Reported Earnings • Oct 21Full year 2025 earnings released: EPS: US$1.66 (vs US$1.06 in FY 2024)Full year 2025 results: EPS: US$1.66 (up from US$1.06 in FY 2024). Revenue: US$32.8m (down 32% from FY 2024). Net income: US$3.88m (up 200% from FY 2024). Profit margin: 12% (up from 2.7% in FY 2024). The increase in margin was driven by lower expenses.Reported Earnings • Apr 28First half 2025 earnings released: US$0.13 loss per share (vs US$0.65 profit in 1H 2024)First half 2025 results: US$0.13 loss per share (down from US$0.65 profit in 1H 2024). Revenue: US$24.0m (up 1.9% from 1H 2024). Net loss: US$232.5k (down 131% from profit in 1H 2024).Reported Earnings • Oct 30Full year 2024 earnings released: EPS: US$0.04 (vs US$0.035 in FY 2023)Full year 2024 results: EPS: US$0.04 (up from US$0.035 in FY 2023). Revenue: US$48.5m (up 72% from FY 2023). Net income: US$1.29m (up 33% from FY 2023). Profit margin: 2.7% (down from 3.4% in FY 2023). The decrease in margin was driven by higher expenses.모든 업데이트 보기Recent updates공시 • May 22Haoxi Health Technology Limited, Annual General Meeting, Jun 02, 2026Haoxi Health Technology Limited, Annual General Meeting, Jun 02, 2026, at 09:30 China Standard Time. Location: at room 801, tower c, floor 8, building 103, huizhongli, chaoyang district, beijing China공시 • May 20Haoxi Health Technology Limited announced that it expects to receive $0.72 million in fundingHaoxi Health Technology Limited announced that it has entered into a Securities Purchase Agreement with Zhen Fan the Company’s Chief Executive Officer and the chairman of the board of the directors pursuant to which the Company agreed to issue and sell to the Purchaser, and the Purchaser agreed to purchase from the Company, 40,000,000 Class B ordinary shares at a par value of $0.0025 per share at an issue price of $0.018 per share for gross proceeds of 720,000 on May 18, 2026. The transaction is subject to the terms and conditions set forth in the Purchase Agreement. The purchase price per Share represents approximately 101.12% of the closing price of the Company’s Class A ordinary shares as reported on Nasdaq.com on May 18, 2026. The issue price per Share represents approximately 101.12% of the closing price of the Company’s Class A ordinary shares as reported on Nasdaq.com on May 18, 2026. The Purchase Agreement contains customary representations, warranties, covenants, closing conditions and indemnification provisions of the Company and the Purchaser. The closing of the transaction is subject to the satisfaction or waiver of customary closing conditions set forth in the Purchase Agreement, including, among others, the delivery of the purchase price by the Purchaser and the issuance of the Shares by the Company. The transaction contemplated by the Purchase Agreement constitutes a related-party transaction. The transaction is approved by audit committee of the Board. The transaction contemplated by the Purchase Agreement is expected to close on or about May 19, 2026.Immediately following the closing of the transaction contemplated by the Purchase Agreement, the Purchaser will beneficially own 40,690,800 Class B ordinary shares, representing approximately 83.83% of the aggregate voting power of the Company’s outstanding ordinary shares.공시 • May 14Haoxi Health Technology Limited has completed a Follow-on Equity Offering in the amount of $6.4558 million.Haoxi Health Technology Limited has completed a Follow-on Equity Offering in the amount of $6.4558 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 9,000,000 Price\Range: $0.25 Discount Per Security: $0.0175 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 16,999,998 Price\Range: $0.2474 Discount Per Security: $0.0173 Transaction Features: Registered Direct Offering공시 • May 13+ 1 more updateHaoxi Health Technology Limited has completed a Follow-on Equity Offering in the amount of $6.4558 million.Haoxi Health Technology Limited has completed a Follow-on Equity Offering in the amount of $6.4558 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 9,000,000 Price\Range: $0.25 Discount Per Security: $0.0175 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 16,999,998 Price\Range: $0.2474 Discount Per Security: $0.0173 Transaction Features: Registered Direct Offering공시 • May 12Haoxi Health Technology Limited has filed a Follow-on Equity Offering in the amount of $4.2725 million.Haoxi Health Technology Limited has filed a Follow-on Equity Offering in the amount of $4.2725 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 9,000,000 Price\Range: $0.0025 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 16,999,998 Price\Range: $0.25 Transaction Features: Registered Direct OfferingReported Earnings • Apr 27First half 2026 earnings released: US$1.53 loss per share (vs US$3.20 loss in 1H 2025)First half 2026 results: US$1.53 loss per share. Revenue: US$33.8m (up 41% from 1H 2025). Net loss: US$6.88m (loss widened US$6.65m from 1H 2025).Valuation Update With 7 Day Price Move • Mar 30Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to US$1.05, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 14x in the Media industry in the US. Total loss to shareholders of 17% over the past year.Valuation Update With 7 Day Price Move • Feb 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to US$1.29, the stock trades at a trailing P/E ratio of 19.7x. Average trailing P/E is 24x in the Media industry in the US. Total loss to shareholders of 29% over the past year.Valuation Update With 7 Day Price Move • Feb 06Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to US$1.10, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 15x in the Media industry in the US. Total loss to shareholders of 42% over the past year.공시 • Jan 24Haoxi Health Technology Limited has filed a Follow-on Equity Offering in the amount of $80 million.Haoxi Health Technology Limited has filed a Follow-on Equity Offering in the amount of $80 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Transaction Features: At the Market OfferingNew Risk • Jan 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (113% accrual ratio). Shareholders have been substantially diluted in the past year (190% increase in shares outstanding). Market cap is less than US$10m (US$9.50m market cap). Minor Risk Share price has been volatile over the past 3 months (9.2% average weekly change).Valuation Update With 7 Day Price Move • Jan 09Investor sentiment improves as stock rises 40%After last week's 40% share price gain to US$1.46, the stock trades at a trailing P/E ratio of 3.1x. Average trailing P/E is 14x in the Media industry in the US. Total loss to shareholders of 62% over the past year.공시 • Dec 04Haoxi Health Technology Limited announced that it has received $5 million in fundingOn December 3, 2025, Haoxi Health Technology Limited closed the transaction.Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improves as stock rises 19%After last week's 19% share price gain to US$1.07, the stock trades at a trailing P/E ratio of 2.3x. Average trailing P/E is 15x in the Media industry in the US. Total loss to shareholders of 67% over the past year.Reported Earnings • Oct 21Full year 2025 earnings released: EPS: US$1.66 (vs US$1.06 in FY 2024)Full year 2025 results: EPS: US$1.66 (up from US$1.06 in FY 2024). Revenue: US$32.8m (down 32% from FY 2024). Net income: US$3.88m (up 200% from FY 2024). Profit margin: 12% (up from 2.7% in FY 2024). The increase in margin was driven by lower expenses.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$1.09, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 20x in the Media industry in the US. Total loss to shareholders of 78% over the past year.Valuation Update With 7 Day Price Move • Sep 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$1.37, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 21x in the Media industry in the US. Total loss to shareholders of 99% over the past year.분석 기사 • Aug 04Here's What's Concerning About Haoxi Health Technology's (NASDAQ:HAO) Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$1.59, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 18x in the Media industry in the US. Total loss to shareholders of 99% over the past year.Valuation Update With 7 Day Price Move • May 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$1.39, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 15x in the Media industry in the US. Total loss to shareholders of 99% over the past year.Reported Earnings • Apr 28First half 2025 earnings released: US$0.13 loss per share (vs US$0.65 profit in 1H 2024)First half 2025 results: US$0.13 loss per share (down from US$0.65 profit in 1H 2024). Revenue: US$24.0m (up 1.9% from 1H 2024). Net loss: US$232.5k (down 131% from profit in 1H 2024).New Risk • Apr 27New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.6% Last year net profit margin: 3.0% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). High level of non-cash earnings (95% accrual ratio). Shareholders have been substantially diluted in the past year (119% increase in shares outstanding). Market cap is less than US$10m (US$3.98m market cap). Minor Risk Profit margins are more than 30% lower than last year (0.6% net profit margin).분석 기사 • Apr 17Market Cool On Haoxi Health Technology Limited's (NASDAQ:HAO) Earnings Pushing Shares 29% LowerTo the annoyance of some shareholders, Haoxi Health Technology Limited ( NASDAQ:HAO ) shares are down a considerable...공시 • Apr 15Haoxi Health Technology Limited Announces CFO ChangesOn April 10, 2025, Ms. Yu Guo notified Haoxi Health Technology Limited of her resignation as Chief Financial Officer (“CFO”) of the Company, effective as of April 10, 2025. Ms. Yu Guo has advised the Company that her resignation was due to personal reasons and not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company. To fill the vacancy created by Ms. Yu Guo’s departure, on April 11, 2025, the Board of Directors the Company appointed Ms. Dongxue Li as CFO, effective on April 12, 2025. The appointment of Ms. Li as CFO has a term of one year and may be extended for successive one-year terms, subject to earlier resignation or removal. She will receive an annual compensation of $12,000. The biographical information of Ms. Li is set forth below. Since August 2024, Ms. Dongxue Li has acted as the financial reporting manager at Beijing Haoxi Digital Technology Co. Ltd., a wholly owned operating subsidiary of the Company. Prior to joining the Company, Ms. Li worked at the Shanghai Youtuo Public Relations Consulting Co. Ltd. from 2012 to 2022, and she served as the senior finance manager of this company from July 2020 to December 2022, in charge of the financial reporting and internal control matters. Ms. Li earned her Bachelor’s degree in Accounting from the Northern College of Beijing University of Chemical Technology in 2011. She obtained the junior accounting professional qualification in China.Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improves as stock rises 31%After last week's 31% share price gain to US$1.28, the stock trades at a trailing P/E ratio of 2.8x. Average trailing P/E is 14x in the Media industry in the US. Total loss to shareholders of 99% over the past year.Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 26%After last week's 26% share price gain to US$1.97, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 13x in the Media industry in the US. Total loss to shareholders of 99% over the past year.Valuation Update With 7 Day Price Move • Mar 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$1.71, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 15x in the Media industry in the US. Total loss to shareholders of 99% over the past year.분석 기사 • Feb 28Haoxi Health Technology Limited (NASDAQ:HAO) Might Not Be As Mispriced As It Looks After Plunging 48%The Haoxi Health Technology Limited ( NASDAQ:HAO ) share price has fared very poorly over the last month, falling by a...공시 • Feb 12Haoxi Health Technology Regains Compliance with Nasdaq Minimum Closing Bid Price RuleHaoxi Health Technology Limited announced that it received a formal notification from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company’s Class A ordinary shares, par value $0.0025 each (the “Ordinary Shares”) to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company’s Ordinary Shares has been at $1.00 per share or greater for the last 10 consecutive business days from January 27, 2025, to February 7, 2025. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and this bid price deficiency matter is now closed.New Risk • Jan 28New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 121% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). High level of non-cash earnings (59% accrual ratio). Shareholders have been substantially diluted in the past year (121% increase in shares outstanding). Market cap is less than US$10m (US$7.29m market cap).Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorates as stock falls 26%After last week's 26% share price decline to US$2.58, the stock trades at a trailing P/E ratio of 38.8x. Average trailing P/E is 14x in the Media industry in the US. Total loss to shareholders of 98% over the past year.분석 기사 • Jan 06Investors Still Aren't Entirely Convinced By Haoxi Health Technology Limited's (NASDAQ:HAO) Earnings Despite 28% Price JumpThose holding Haoxi Health Technology Limited ( NASDAQ:HAO ) shares would be relieved that the share price has...공시 • Dec 20Haoxi Health Technology Limited, Annual General Meeting, Jan 10, 2025Haoxi Health Technology Limited, Annual General Meeting, Jan 10, 2025, at 10:00 China Standard Time. Location: room 801, tower c, floor 8, building 103, huizhongli, chaoyang district, beijing China분석 기사 • Nov 22Haoxi Health Technology Limited (NASDAQ:HAO) Soars 31% But It's A Story Of Risk Vs RewardThose holding Haoxi Health Technology Limited ( NASDAQ:HAO ) shares would be relieved that the share price has...Reported Earnings • Oct 30Full year 2024 earnings released: EPS: US$0.04 (vs US$0.035 in FY 2023)Full year 2024 results: EPS: US$0.04 (up from US$0.035 in FY 2023). Revenue: US$48.5m (up 72% from FY 2023). Net income: US$1.29m (up 33% from FY 2023). Profit margin: 2.7% (down from 3.4% in FY 2023). The decrease in margin was driven by higher expenses.공시 • Oct 07Haoxi Health Technology Limited Provides Preliminary Unaudited Earnings Guidance for the Fiscal Year Ended June 30, 2024Haoxi Health Technology Limited provided preliminary unaudited earnings guidance for the fiscal year ended June 30, 2024. For the year, the company expects revenue to be approximately $48.52 million, reflecting a 72% increase compared to $28.23 million in the fiscal year ended June 30, 2023 (FY23). Net Income to be approximately $1.29 million, reflecting a 33.2% increase from $0.97 million in FY23.공시 • Sep 20Haoxi Health Technology Limited has completed a Composite Units Offering in the amount of $12 million.Haoxi Health Technology Limited has completed a Composite Units Offering in the amount of $12 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 4,000,000 Price\Range: $3 Discount Per Security: $0.21New Risk • Sep 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$91.2m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (24% average weekly change). Minor Risk Market cap is less than US$100m (US$91.2m market cap).Valuation Update With 7 Day Price Move • Sep 17Investor sentiment deteriorates as stock falls 29%After last week's 29% share price decline to US$2.83, the stock trades at a trailing P/E ratio of 71.1x. Average trailing P/E is 14x in the Media industry in the US.Valuation Update With 7 Day Price Move • Aug 15Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to US$3.07, the stock trades at a trailing P/E ratio of 77.2x. Average trailing P/E is 12x in the Media industry in the US.New Risk • Aug 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$89.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (23% average weekly change). Minor Risk Market cap is less than US$100m (US$89.6m market cap).Board Change • Feb 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. CEO & Chairman of the Board of Directors Zhen Fan is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.매출 및 비용 세부 내역Haoxi Health Technology가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:HAO 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 2543-310030 Sep 253816030 Jun 253343031 Mar 254122031 Dec 244901030 Sep 244911030 Jun 244911031 Mar 244611031 Dec 234311030 Sep 233511030 Jun 232811031 Mar 232311031 Dec 221810030 Sep 221700030 Jun 221600030 Jun 2113000양질의 수익: HAO 은(는) 현재 수익성이 없습니다.이익 마진 증가: HAO는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: HAO는 수익성이 없지만 지난 5년 동안 연평균 3.8%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 HAO의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: HAO은 수익성이 없어 지난 해 수익 성장률을 Media 업계(5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: HAO는 현재 수익성이 없으므로 자본 수익률이 음수(-17.37%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMedia 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/12 01:12종가2026/07/10 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Haoxi Health Technology Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Apr 27First half 2026 earnings released: US$1.53 loss per share (vs US$3.20 loss in 1H 2025)First half 2026 results: US$1.53 loss per share. Revenue: US$33.8m (up 41% from 1H 2025). Net loss: US$6.88m (loss widened US$6.65m from 1H 2025).
Reported Earnings • Oct 21Full year 2025 earnings released: EPS: US$1.66 (vs US$1.06 in FY 2024)Full year 2025 results: EPS: US$1.66 (up from US$1.06 in FY 2024). Revenue: US$32.8m (down 32% from FY 2024). Net income: US$3.88m (up 200% from FY 2024). Profit margin: 12% (up from 2.7% in FY 2024). The increase in margin was driven by lower expenses.
Reported Earnings • Apr 28First half 2025 earnings released: US$0.13 loss per share (vs US$0.65 profit in 1H 2024)First half 2025 results: US$0.13 loss per share (down from US$0.65 profit in 1H 2024). Revenue: US$24.0m (up 1.9% from 1H 2024). Net loss: US$232.5k (down 131% from profit in 1H 2024).
Reported Earnings • Oct 30Full year 2024 earnings released: EPS: US$0.04 (vs US$0.035 in FY 2023)Full year 2024 results: EPS: US$0.04 (up from US$0.035 in FY 2023). Revenue: US$48.5m (up 72% from FY 2023). Net income: US$1.29m (up 33% from FY 2023). Profit margin: 2.7% (down from 3.4% in FY 2023). The decrease in margin was driven by higher expenses.
공시 • May 22Haoxi Health Technology Limited, Annual General Meeting, Jun 02, 2026Haoxi Health Technology Limited, Annual General Meeting, Jun 02, 2026, at 09:30 China Standard Time. Location: at room 801, tower c, floor 8, building 103, huizhongli, chaoyang district, beijing China
공시 • May 20Haoxi Health Technology Limited announced that it expects to receive $0.72 million in fundingHaoxi Health Technology Limited announced that it has entered into a Securities Purchase Agreement with Zhen Fan the Company’s Chief Executive Officer and the chairman of the board of the directors pursuant to which the Company agreed to issue and sell to the Purchaser, and the Purchaser agreed to purchase from the Company, 40,000,000 Class B ordinary shares at a par value of $0.0025 per share at an issue price of $0.018 per share for gross proceeds of 720,000 on May 18, 2026. The transaction is subject to the terms and conditions set forth in the Purchase Agreement. The purchase price per Share represents approximately 101.12% of the closing price of the Company’s Class A ordinary shares as reported on Nasdaq.com on May 18, 2026. The issue price per Share represents approximately 101.12% of the closing price of the Company’s Class A ordinary shares as reported on Nasdaq.com on May 18, 2026. The Purchase Agreement contains customary representations, warranties, covenants, closing conditions and indemnification provisions of the Company and the Purchaser. The closing of the transaction is subject to the satisfaction or waiver of customary closing conditions set forth in the Purchase Agreement, including, among others, the delivery of the purchase price by the Purchaser and the issuance of the Shares by the Company. The transaction contemplated by the Purchase Agreement constitutes a related-party transaction. The transaction is approved by audit committee of the Board. The transaction contemplated by the Purchase Agreement is expected to close on or about May 19, 2026.Immediately following the closing of the transaction contemplated by the Purchase Agreement, the Purchaser will beneficially own 40,690,800 Class B ordinary shares, representing approximately 83.83% of the aggregate voting power of the Company’s outstanding ordinary shares.
공시 • May 14Haoxi Health Technology Limited has completed a Follow-on Equity Offering in the amount of $6.4558 million.Haoxi Health Technology Limited has completed a Follow-on Equity Offering in the amount of $6.4558 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 9,000,000 Price\Range: $0.25 Discount Per Security: $0.0175 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 16,999,998 Price\Range: $0.2474 Discount Per Security: $0.0173 Transaction Features: Registered Direct Offering
공시 • May 13+ 1 more updateHaoxi Health Technology Limited has completed a Follow-on Equity Offering in the amount of $6.4558 million.Haoxi Health Technology Limited has completed a Follow-on Equity Offering in the amount of $6.4558 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 9,000,000 Price\Range: $0.25 Discount Per Security: $0.0175 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 16,999,998 Price\Range: $0.2474 Discount Per Security: $0.0173 Transaction Features: Registered Direct Offering
공시 • May 12Haoxi Health Technology Limited has filed a Follow-on Equity Offering in the amount of $4.2725 million.Haoxi Health Technology Limited has filed a Follow-on Equity Offering in the amount of $4.2725 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 9,000,000 Price\Range: $0.0025 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 16,999,998 Price\Range: $0.25 Transaction Features: Registered Direct Offering
Reported Earnings • Apr 27First half 2026 earnings released: US$1.53 loss per share (vs US$3.20 loss in 1H 2025)First half 2026 results: US$1.53 loss per share. Revenue: US$33.8m (up 41% from 1H 2025). Net loss: US$6.88m (loss widened US$6.65m from 1H 2025).
Valuation Update With 7 Day Price Move • Mar 30Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to US$1.05, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 14x in the Media industry in the US. Total loss to shareholders of 17% over the past year.
Valuation Update With 7 Day Price Move • Feb 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to US$1.29, the stock trades at a trailing P/E ratio of 19.7x. Average trailing P/E is 24x in the Media industry in the US. Total loss to shareholders of 29% over the past year.
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to US$1.10, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 15x in the Media industry in the US. Total loss to shareholders of 42% over the past year.
공시 • Jan 24Haoxi Health Technology Limited has filed a Follow-on Equity Offering in the amount of $80 million.Haoxi Health Technology Limited has filed a Follow-on Equity Offering in the amount of $80 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Transaction Features: At the Market Offering
New Risk • Jan 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (113% accrual ratio). Shareholders have been substantially diluted in the past year (190% increase in shares outstanding). Market cap is less than US$10m (US$9.50m market cap). Minor Risk Share price has been volatile over the past 3 months (9.2% average weekly change).
Valuation Update With 7 Day Price Move • Jan 09Investor sentiment improves as stock rises 40%After last week's 40% share price gain to US$1.46, the stock trades at a trailing P/E ratio of 3.1x. Average trailing P/E is 14x in the Media industry in the US. Total loss to shareholders of 62% over the past year.
공시 • Dec 04Haoxi Health Technology Limited announced that it has received $5 million in fundingOn December 3, 2025, Haoxi Health Technology Limited closed the transaction.
Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improves as stock rises 19%After last week's 19% share price gain to US$1.07, the stock trades at a trailing P/E ratio of 2.3x. Average trailing P/E is 15x in the Media industry in the US. Total loss to shareholders of 67% over the past year.
Reported Earnings • Oct 21Full year 2025 earnings released: EPS: US$1.66 (vs US$1.06 in FY 2024)Full year 2025 results: EPS: US$1.66 (up from US$1.06 in FY 2024). Revenue: US$32.8m (down 32% from FY 2024). Net income: US$3.88m (up 200% from FY 2024). Profit margin: 12% (up from 2.7% in FY 2024). The increase in margin was driven by lower expenses.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$1.09, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 20x in the Media industry in the US. Total loss to shareholders of 78% over the past year.
Valuation Update With 7 Day Price Move • Sep 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$1.37, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 21x in the Media industry in the US. Total loss to shareholders of 99% over the past year.
분석 기사 • Aug 04Here's What's Concerning About Haoxi Health Technology's (NASDAQ:HAO) Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$1.59, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 18x in the Media industry in the US. Total loss to shareholders of 99% over the past year.
Valuation Update With 7 Day Price Move • May 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$1.39, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 15x in the Media industry in the US. Total loss to shareholders of 99% over the past year.
Reported Earnings • Apr 28First half 2025 earnings released: US$0.13 loss per share (vs US$0.65 profit in 1H 2024)First half 2025 results: US$0.13 loss per share (down from US$0.65 profit in 1H 2024). Revenue: US$24.0m (up 1.9% from 1H 2024). Net loss: US$232.5k (down 131% from profit in 1H 2024).
New Risk • Apr 27New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.6% Last year net profit margin: 3.0% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). High level of non-cash earnings (95% accrual ratio). Shareholders have been substantially diluted in the past year (119% increase in shares outstanding). Market cap is less than US$10m (US$3.98m market cap). Minor Risk Profit margins are more than 30% lower than last year (0.6% net profit margin).
분석 기사 • Apr 17Market Cool On Haoxi Health Technology Limited's (NASDAQ:HAO) Earnings Pushing Shares 29% LowerTo the annoyance of some shareholders, Haoxi Health Technology Limited ( NASDAQ:HAO ) shares are down a considerable...
공시 • Apr 15Haoxi Health Technology Limited Announces CFO ChangesOn April 10, 2025, Ms. Yu Guo notified Haoxi Health Technology Limited of her resignation as Chief Financial Officer (“CFO”) of the Company, effective as of April 10, 2025. Ms. Yu Guo has advised the Company that her resignation was due to personal reasons and not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company. To fill the vacancy created by Ms. Yu Guo’s departure, on April 11, 2025, the Board of Directors the Company appointed Ms. Dongxue Li as CFO, effective on April 12, 2025. The appointment of Ms. Li as CFO has a term of one year and may be extended for successive one-year terms, subject to earlier resignation or removal. She will receive an annual compensation of $12,000. The biographical information of Ms. Li is set forth below. Since August 2024, Ms. Dongxue Li has acted as the financial reporting manager at Beijing Haoxi Digital Technology Co. Ltd., a wholly owned operating subsidiary of the Company. Prior to joining the Company, Ms. Li worked at the Shanghai Youtuo Public Relations Consulting Co. Ltd. from 2012 to 2022, and she served as the senior finance manager of this company from July 2020 to December 2022, in charge of the financial reporting and internal control matters. Ms. Li earned her Bachelor’s degree in Accounting from the Northern College of Beijing University of Chemical Technology in 2011. She obtained the junior accounting professional qualification in China.
Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improves as stock rises 31%After last week's 31% share price gain to US$1.28, the stock trades at a trailing P/E ratio of 2.8x. Average trailing P/E is 14x in the Media industry in the US. Total loss to shareholders of 99% over the past year.
Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 26%After last week's 26% share price gain to US$1.97, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 13x in the Media industry in the US. Total loss to shareholders of 99% over the past year.
Valuation Update With 7 Day Price Move • Mar 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$1.71, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 15x in the Media industry in the US. Total loss to shareholders of 99% over the past year.
분석 기사 • Feb 28Haoxi Health Technology Limited (NASDAQ:HAO) Might Not Be As Mispriced As It Looks After Plunging 48%The Haoxi Health Technology Limited ( NASDAQ:HAO ) share price has fared very poorly over the last month, falling by a...
공시 • Feb 12Haoxi Health Technology Regains Compliance with Nasdaq Minimum Closing Bid Price RuleHaoxi Health Technology Limited announced that it received a formal notification from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company’s Class A ordinary shares, par value $0.0025 each (the “Ordinary Shares”) to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company’s Ordinary Shares has been at $1.00 per share or greater for the last 10 consecutive business days from January 27, 2025, to February 7, 2025. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and this bid price deficiency matter is now closed.
New Risk • Jan 28New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 121% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). High level of non-cash earnings (59% accrual ratio). Shareholders have been substantially diluted in the past year (121% increase in shares outstanding). Market cap is less than US$10m (US$7.29m market cap).
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorates as stock falls 26%After last week's 26% share price decline to US$2.58, the stock trades at a trailing P/E ratio of 38.8x. Average trailing P/E is 14x in the Media industry in the US. Total loss to shareholders of 98% over the past year.
분석 기사 • Jan 06Investors Still Aren't Entirely Convinced By Haoxi Health Technology Limited's (NASDAQ:HAO) Earnings Despite 28% Price JumpThose holding Haoxi Health Technology Limited ( NASDAQ:HAO ) shares would be relieved that the share price has...
공시 • Dec 20Haoxi Health Technology Limited, Annual General Meeting, Jan 10, 2025Haoxi Health Technology Limited, Annual General Meeting, Jan 10, 2025, at 10:00 China Standard Time. Location: room 801, tower c, floor 8, building 103, huizhongli, chaoyang district, beijing China
분석 기사 • Nov 22Haoxi Health Technology Limited (NASDAQ:HAO) Soars 31% But It's A Story Of Risk Vs RewardThose holding Haoxi Health Technology Limited ( NASDAQ:HAO ) shares would be relieved that the share price has...
Reported Earnings • Oct 30Full year 2024 earnings released: EPS: US$0.04 (vs US$0.035 in FY 2023)Full year 2024 results: EPS: US$0.04 (up from US$0.035 in FY 2023). Revenue: US$48.5m (up 72% from FY 2023). Net income: US$1.29m (up 33% from FY 2023). Profit margin: 2.7% (down from 3.4% in FY 2023). The decrease in margin was driven by higher expenses.
공시 • Oct 07Haoxi Health Technology Limited Provides Preliminary Unaudited Earnings Guidance for the Fiscal Year Ended June 30, 2024Haoxi Health Technology Limited provided preliminary unaudited earnings guidance for the fiscal year ended June 30, 2024. For the year, the company expects revenue to be approximately $48.52 million, reflecting a 72% increase compared to $28.23 million in the fiscal year ended June 30, 2023 (FY23). Net Income to be approximately $1.29 million, reflecting a 33.2% increase from $0.97 million in FY23.
공시 • Sep 20Haoxi Health Technology Limited has completed a Composite Units Offering in the amount of $12 million.Haoxi Health Technology Limited has completed a Composite Units Offering in the amount of $12 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 4,000,000 Price\Range: $3 Discount Per Security: $0.21
New Risk • Sep 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$91.2m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (24% average weekly change). Minor Risk Market cap is less than US$100m (US$91.2m market cap).
Valuation Update With 7 Day Price Move • Sep 17Investor sentiment deteriorates as stock falls 29%After last week's 29% share price decline to US$2.83, the stock trades at a trailing P/E ratio of 71.1x. Average trailing P/E is 14x in the Media industry in the US.
Valuation Update With 7 Day Price Move • Aug 15Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to US$3.07, the stock trades at a trailing P/E ratio of 77.2x. Average trailing P/E is 12x in the Media industry in the US.
New Risk • Aug 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$89.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (23% average weekly change). Minor Risk Market cap is less than US$100m (US$89.6m market cap).
Board Change • Feb 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. CEO & Chairman of the Board of Directors Zhen Fan is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.